Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03937986 · ClinicalTrials.gov registry record · Early Phase 1
Suvorexant and Cocaine
A Early Phase 1 study, sponsored by William Stoops.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT03937986: Completed Early Phase 1 study, sponsored by William Stoops.
NCT03937986 is a Early Phase 1 study that has completed, run by William Stoops. The registered enrollment target is 8 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03937986, a Early Phase 1 study, has completed, sponsored by William Stoops.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The research proposed here will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for cocaine, as well as other cocaine-associated maladaptive behaviors in active cocaine users. This study will also provide basic science information about the orexinergic mechanisms underlying the pharmacodynamic effects of cocaine in humans. As such the outcomes will contribute to our understanding of the clinical neurobiology of cocaine use disorder. Overall, the proposed work seeks to expand the scope of current clinical neuroscience research on cocaine addiction by focusing on orexin, which has strong preclinical evidence supporting its critical role in addiction but remains unstudied in humans.
Primary Outcome
Number of Times Subjects Choose Cocaine (Maximum of 10 Choices) Over Money
Interventions
- DRUG Placebo oral capsule
- DRUG Suvorexant
- DRUG Cocaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-07-11 |
| Est. Completion | 2022-04-30 |
| Phase | Early Phase 1 |
What the finished NCT03937986 record still lists
NCT03937986 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo oral capsule is the first listed.
NCT03937986 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03937986 about?
NCT03937986 is a clinical study titled "Suvorexant and Cocaine". The research proposed here will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for cocaine, as well as other cocaine-associated maladaptive behaviors in active cocaine users. This study will also provide basic science ...
What is the current status of trial NCT03937986?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2019-07-11. Estimated completion is 2022-04-30.
What interventions are being tested in trial NCT03937986?
The interventions under investigation include: Placebo oral capsule (DRUG), Suvorexant (DRUG), Cocaine (DRUG).
Who is sponsoring clinical trial NCT03937986?
This trial is sponsored by William Stoops, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03937986's enrollment target sits among peer trials
8 1783rd of 2000 higher than 176 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI